CXCL9 and hepatocellular carcinoma: Therefore, the chemokine, CXCL9, and UBD, which is a marker of immune activation in hepatocellular carcinoma and colon carcinoma [61], are preferentially induced by type II interferon in both professional immune and non-immune cells.